Brokers Set Expectations for TARA Q1 Earnings

Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) - Analysts at Lifesci Capital issued their Q1 2025 earnings per share estimates for Protara Therapeutics in a report released on Tuesday, March 11th. Lifesci Capital analyst C. Zhu anticipates that the company will post earnings of ($0.37) per share for the quarter. Lifesci Capital has a "Outperform" rating and a $22.00 price objective on the stock. The consensus estimate for Protara Therapeutics' current full-year earnings is ($3.32) per share. Lifesci Capital also issued estimates for Protara Therapeutics' Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.52) EPS, Q4 2025 earnings at ($0.60) EPS, FY2025 earnings at ($1.93) EPS, Q1 2026 earnings at ($0.57) EPS, Q2 2026 earnings at ($0.60) EPS, Q3 2026 earnings at ($0.68) EPS, Q4 2026 earnings at ($0.77) EPS and FY2026 earnings at ($2.67) EPS.

TARA has been the subject of several other research reports. Cantor Fitzgerald assumed coverage on Protara Therapeutics in a research note on Friday. They set an "overweight" rating for the company. Guggenheim restated a "buy" rating and issued a $20.00 price objective on shares of Protara Therapeutics in a report on Friday, December 6th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $23.00 target price on shares of Protara Therapeutics in a research note on Thursday, March 6th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $22.50.

Remove Ads

Protara Therapeutics Stock Performance

Shares of NASDAQ TARA traded up $0.11 during midday trading on Thursday, reaching $4.42. 150,549 shares of the stock were exchanged, compared to its average volume of 786,968. The stock has a market capitalization of $91.18 million, a P/E ratio of -1.57 and a beta of 1.69. The company has a 50 day simple moving average of $4.42 and a 200 day simple moving average of $3.49. Protara Therapeutics has a twelve month low of $1.60 and a twelve month high of $10.48.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last announced its quarterly earnings data on Wednesday, March 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.57) by $0.09.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in TARA. HBK Investments L P acquired a new stake in Protara Therapeutics in the fourth quarter valued at approximately $106,000. Squarepoint Ops LLC acquired a new stake in shares of Protara Therapeutics in the 4th quarter valued at $110,000. Dimensional Fund Advisors LP purchased a new stake in shares of Protara Therapeutics during the 4th quarter worth $111,000. Bailard Inc. acquired a new position in shares of Protara Therapeutics during the fourth quarter worth $157,000. Finally, XTX Topco Ltd purchased a new position in Protara Therapeutics in the third quarter valued at $60,000. Institutional investors and hedge funds own 38.13% of the company's stock.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.